Literature DB >> 23600966

High carrier frequency of 21-hydroxylase deficiency in Cyprus.

A A P Phedonos1, C Shammas, N Skordis, T C Kyriakides, V Neocleous, L A Phylactou.   

Abstract

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is a common autosomal recessive disorder caused by mutations in the CYP21A2 gene. The carrier frequency of CYP21A2 mutations has been estimated to be 1:25 to 1:10 on the basis of newborn screening. The main objective of this study was to determine the carrier frequency in the Cypriot population of mutations in the CYP21A2 gene. Three hundred unrelated subjects (150 males and 150 females) from the general population of Cyprus were screened for mutations in the CYP21A2 gene and its promoter. The CYP21A2 genotype analysis identified six different mutants and revealed a carrier frequency of 9.83% with the mild p.Val281Leu being the most frequent (4.3%), followed by p.Qln318stop (2.5%), p.Pro453Ser (1.33%), p.Val304Met (0.83%), p.Pro482Ser (0.67%) and p.Met283Val (0.17%). The notable high CYP21A2 carrier frequency of the Cypriot population is one of the highest reported so far by genotype analysis. Knowledge of the mutational spectrum of CYP21A2 will enable to optimize mutation detection strategy for genetic diagnosis of 21-OHD not only in Cyprus, but also the greater Mediterranean region.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  21-hydroxylase deficiency; CYP21A2 gene; Cyprus; congenital adrenal hyperplasia

Mesh:

Substances:

Year:  2013        PMID: 23600966     DOI: 10.1111/cge.12153

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

Review 1.  Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome.

Authors:  Henrik Falhammar; Anna Nordenström
Journal:  Endocrine       Date:  2015-06-17       Impact factor: 3.633

2.  Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene.

Authors:  Pavlos Fanis; Nicos Skordis; Leonidas A Phylactou; Vassos Neocleous
Journal:  Hormones (Athens)       Date:  2022-10-20       Impact factor: 3.419

3.  Genetic defects of the CYP21A2 gene in girls with premature adrenarche.

Authors:  N Skordis; C Shammas; A A P Phedonos; A Kyriakou; M Toumba; V Neocleous; L A Phylactou
Journal:  J Endocrinol Invest       Date:  2014-12-07       Impact factor: 4.256

Review 4.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

5.  Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations.

Authors:  Vassos Neocleous; Christos Shammas; Alexia Ap Phedonos; Leonidas A Phylactou; Nicos Skordis
Journal:  Indian J Endocrinol Metab       Date:  2014-11

6.  Variations in the 3'UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia.

Authors:  Vassos Neocleous; Pavlos Fanis; Meropi Toumba; Alexia A P Phedonos; Michalis Picolos; Elena Andreou; Tassos C Kyriakides; George A Tanteles; Christos Shammas; Leonidas A Phylactou; Nicos Skordis
Journal:  Int J Endocrinol       Date:  2017-04-12       Impact factor: 3.257

7.  Revisiting the prevalence of nonclassic congenital adrenal hyperplasia in US Ashkenazi Jews and Caucasians.

Authors:  Fady Hannah-Shmouni; Rachel Morissette; Ninet Sinaii; Meredith Elman; Toni R Prezant; Wuyan Chen; Ann Pulver; Deborah P Merke
Journal:  Genet Med       Date:  2017-05-25       Impact factor: 8.822

8.  Pathological variants in genes associated with disorders of sex development and central causes of hypogonadism in a whole-genome reference panel of 8380 Japanese individuals.

Authors:  Naomi Shiga; Yumi Yamaguchi-Kabata; Saori Igeta; Jun Yasuda; Shu Tadaka; Takamichi Minato; Zen Watanabe; Junko Kanno; Gen Tamiya; Nobuo Fuse; Kengo Kinoshita; Shigeo Kure; Akiko Kondo; Masahito Tachibana; Masayuki Yamamoto; Nobuo Yaegashi; Junichi Sugawara
Journal:  Hum Genome Var       Date:  2022-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.